Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From PARI GmbH
Neuroscience and oncology fuel high hopes for therapeutic R&D progress among 90-plus surveyed biopharma industry leaders.
Spexis is hoping to get ColiFin, a therapy for chronic lung infections in cystic fibrosis patients, onto the US market but cannot start the necessary late-stage program without an injection of cash.
Around 100 executives highlight the hot areas to watch on the R&D front in 2021. From cancer to CNS and from regenerative medicine to real world data, expectations are high on many fronts.
Italy’s privately held Zambon could pay up to €500m to bulk up its respiratory products pipeline, producing a nice return for Breath Therapeutics’ syndicate of European investors.
- Medical Devices
- Drug Delivery
- Site Specific
- Other Names / Subsidiaries
- PARI Medical Holding
- PARI Pharma GmbH
- PARltec GmbH
- PARI Worldwide, PARI Respiratory Equipment, Inc.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.